Physicochemical and biological characterization of SB2, a biosimilar of Remicade® (infliximab)

mAbs

Volumn 9, Issue 2, 2017, Pages 364-382

  Hong, Juyong ^a   Lee, Yuhwa ^a   Lee, Changsoo ^a   Eo, Suhyeon ^a   Kim, Soyeon ^a   Lee, Nayoung ^a   Park, Jongmin ^a   Park, Seungkyu ^a   Seo, Donghyuck ^a   Jeong, Min ^a   Lee, Youngji ^a   Yeon, Soojeong ^a   Bou Assaf, George ^b   Sosic, Zoran ^b   Zhang, Wei ^b   Jaquez, Orlando ^c  

^a Samsung Bioepis Co Ltd   (South Korea)

^b BIOGEN   (United States)

^c Biogen Idec International GmbH   (Switzerland)

Author keywords

Biosimilar; critical quality attribute; flixabi; infliximab; renflexis; SB2

Indexed keywords

BIOSIMILAR AGENT; FC RECEPTOR; INFLIXIMAB; SB2 BIOSIMILAR AGENT; TUMOR NECROSIS FACTOR; UNCLASSIFIED DRUG;

ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; APOPTOSIS ASSAY; BINDING AFFINITY; BIOASSAY; BIOLOGICAL ACTIVITY; CAPILLARY ISOELECTRIC FOCUSING; CIRCULAR DICHROISM; COMPLEMENT DEPENDENT CYTOTOXICITY; DEUTERIUM HYDROGEN EXCHANGE; DIFFERENTIAL SCANNING CALORIMETRY; DRUG EFFICACY; DRUG TOLERANCE; ELECTROSPRAY MASS SPECTROMETRY; ENTROPY; ENZYME ACTIVITY; ENZYME LINKED IMMUNOSORBENT ASSAY; FLOW RATE; FLUORESCENCE RESONANCE ENERGY TRANSFER; GLYCOSYLATION; HYDROPHILIC INTERACTION CHROMATOGRAPHY; ION EXCHANGE CHROMATOGRAPHY; MASS SPECTROMETRY; MOLECULAR WEIGHT; NONHUMAN; PEPTIDE MAPPING; PHYSICAL CHEMISTRY; RECEPTOR BINDING ASSAY; SEDIMENTATION RATE; SERODIAGNOSIS; SIZE EXCLUSION CHROMATOGRAPHY; STRUCTURE ACTIVITY RELATION; ULTRA PERFORMANCE LIQUID CHROMATOGRAPHY; ULTRACENTRIFUGATION; ULTRAVIOLET RADIATION; ANIMAL; CHEMISTRY; HUMAN;

ANIMALS; BIOSIMILAR PHARMACEUTICALS; HUMANS; INFLIXIMAB;

EID: 85009739531     PISSN: 19420862     EISSN: 19420870     Source Type: Journal    
DOI: 10.1080/19420862.2016.1264550     Document Type: Article

References (46)

1. Dorner T, Strand V, Cornes P, Gonçalves J, Gulácsi L, Kay J, Kvien TK, Smolen J, Tanaka Y, Burmester GR. The changing landscape of biosimilars in rheumatology. Ann Rheum Dis 2016; 0:1-9; PMID:26964144; http://dx.doi.org/10.1136/annrheumdis-2016-209166
2. Gascon P. The evolving role of biosimilars in haematology-oncology:a practical perspective. Ther Adv Hematol 2015; 6:267-81; PMID:26622996; http://dx.doi.org/10.1177/2040620715613715
3. Niazi SK. Biosimilars and interchangeable biologics:Strategic elements Boca Raton, FL:CRC Press, 2016.
4. European Medicines Agency, Committee for Medicinal Products for Human Use. EMA/CHMP/589317/2013. http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_Public_assessment_report/human/002576/WC500151486.pdf. Accessed April30, 2016.
5. European Medicines Agency, Committee for Medicinal Products for Human Use. EMA/CHMP/819219/2015. http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_Public_assessment_report/human/004007/WC500200380.pdf. Accessed April30, 2016.
6. European Medicines Agency, Committee for Medicinal Products for Human Use. EMA/CHMP/272283/2016. http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_Public_assessment_report/human/004020/WC500208358.pdf. Accessed April30, 2016.
7. Weise M, Bielsky MC, De Smet K, Ehmann F, Ekman N, Narayanan G, Heim HK, Heinonen E, Ho K, Thorpe R, et al. Biosimilars-why terminology matters. Nat Biotechnol 2011; 29:690-3; PMID:21822237; http://dx.doi.org/10.1038/nbt.1936
8. Beck A, Wurch T, Bailly C, Corvaia N. Strategies and challenges for the next generation of therapeutic antibodies. Nat Rev Immunol 2010; 10:345-52; PMID:20414207; http://dx.doi.org/10.1038/nri2747
9. US Food and Drug Administration. Title VII—Improving access to innovative medical therapies:Subtitle A—Biologics price competition and innovation. http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/ucm216146.pdf. Accessed April30, 2016.
10. Cho IH, Lee N, Song D, Jung SY, Bou-Assaf G, Sosic Z, Zhang W, Lyubarskaya Y. Evaluation of the structural, physicochemical, and biological characteristics of SB4, a biosimilar of etanercept [published online ahead of print May 31, 2016]. mAbs 2016; 8(6):1136-55; PMID:27246928; http://dx.doi.org/10.1080/19420862.2016.1193659
11. Knight DM, Trinh H, Le J, Siegel S, Shealy D, McDonough M, Scallon B, Moore MA, Vilcek J, Daddona P. Construction and initial characterization of a mouse-human chimeric anti-TNF antibody. Mol Immunol 1993; 30:1443-53; PMID:8232330; http://dx.doi.org/10.1016/0161-5890(93)90106-L
12. Remicade Prescribing Information (Janssen Biotech, Inc). Available from:http://www.remicade.com/shared/product/remicade/prescribing-information.pdf. Accessed April30, 2016.
13. International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use. ICH Tripartite Guideline. Specifications:test procedures and acceptance criteria for biotechnological/biological products Q6B. Recommended for adoption on March 10, 1999. http://www.gmp-compliance.org/guidemgr/files/3-1-17.pdf. Accessed January20, 2016.
14. US Food and Drug Administration. Guidance for industry:quality considerations in demonstrating biosimilarity of a therapeutic protein product to a reference product. http://www.fda.gov/downloads/drugs/guidancecomplianceregulatoryinformation/guidances/ucm291134.pdf. Published April 2015 Accessed January20, 2016.
15. Schiestl M, Stangler T, Torella C, Cepeljnik T, Toll H, Grau R. Acceptable changes in quality attributes of glycosylated biopharmaceuticals. Nat Biotechnol 2011; 29:310-2; PMID:21478841; http://dx.doi.org/10.1038/nbt.1839
16. European Medicines Agency, Committee for Medicinal Products for Human Use. Guideline on similar biological medicinal products containing biotechnology-derived proteins as active substance:quality issues (revision 1). http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2014/06/WC500167838.pdf. Updated May 22, 2014 Accessed February5, 2016.
17. European Medicines Agency, Committee for Medicinal Products for Human Use. Guideline on similar biological medicinal products [Internet]. London, UK:European Medicines Agency; [Adopted on October 23, 2014; cited February 5, 2016]. Available from:http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2014/10/WC500176768.pdf
18. Chamberlain J. Biosimilars and analytical challenges. Pharm J 2009. http://www.pharmaceutical-journal.com/news-and-analysis/news/biosimilars-and-analytical-challenges/10971836.article. Accessed April30, 2016.
19. Zhong X, Wright JF. Biological insights into therapeutic protein modifications throughout trafficking and their biopharmaceutical applications. Int J Cell Biol 2013; 2013:273086; PMID:23690780; http://dx.doi.org/10.1155/2013/273086. Accessed April30, 2016.
20. Wang X, Li O, Davies M. Higher-order structure comparability:case studies of biosimilar monoclonal antibodies. Bioprocess Int 2014; 12:32-47.
21. Houde D, Berkowitz SA, Engen JR. The utility of hydrogen deuterium exchange mass spectrometry in biopharmaceutical comparability studies. J Pharm Sci 2011; 100:2071-86; PMID:21491437; http://dx.doi.org/10.1002/jps.22432
22. Wang X, Li Q Davis M. Development of antibody arrays for monoclonal antibody higher order structure analysis. Front Pharmacol 2013; 4(Article 103):1-8; PMID:23970865; http://dx.doi.org/10.3389/fphar.2013.00103
23. US Food and Drug Administration. Guidance for industry:immunogenicity assessment for therapeutic protein products. http://www.fda.gov/downloads/drugs/guidancecomplianceregulatoryinformation/guidances/ucm338856.pdf. Published August 2014 Accessed Apr30, 2016.
24. Rosenberg AS. Effects of protein aggregates:an immunologic perspective. AAPS J 2006; 8:E501-7; PMID:17025268; http://dx.doi.org/10.1208/aapsj080359
25. Pilo JS. A critical review of methods for size characterization of non-particulate protein aggregates. Current Pharm Biotechnol 2009; 10:359-72; PMID:19519411; http://dx.doi.org/10.2174/138920109788488815
26. Putnam WS, Prabhu S, Zheng Y, Subramanyam M, Wang YM. Pharmacokinetic, pharmacodynamics and immunogenicity comparability assessment strategies for monoclonal antibodies. Trends in Biotechnol 2010; 28(10):509-516; PMID:20691488; http://dx.doi.org/10.1016/j.tibtech.2010.07.001
27. Shields RL, Lai J, Keck R, O'Connell LY, Hong K, Meng YG, Weikert SH, Presta LG. Lack of fucose on human IgG1 N-linked oligosaccharide improves binding to human Fc RIII and antibody-dependent cellular toxicity. J Biol Chem 2002; 277:26733-40; PMID:11986321; http://dx.doi.org/10.1074/jbc.M202069200
28. Raju TS. Terminal sugars of Fc glycans influence antibody effector functions of IgGs. Curr Opin Immunol 2008; 20:4718; PMID:18606225; http://dx.doi.org/10.1016/j.coi.2008.06.007
29. Butler M, Spearman M. The choice of mammalian cell host and possibilities for glycosylation engineering. Curr Opin Immunol 2014; 30:107-112; PMID:25005678; http://dx.doi.org/10.1016/j.copbio.2014.06.010
30. van Beers MMC Bardor M. Minimizing immunogenicity of biopharmaceuticals by controlling critical quality attributes of proteins. Biotechnol J 2012; 7:1-12; PMID:23027660; http://dx.doi.org/10.1002/biot.201200065
31. Flynn GC, Chen X, Liu YD, Shah B, Zhang Z. Naturally occurring glycan forms of human immunoglobulins G1 and G2. Mol Immunol 2010; 47:2074-82; PMID:2044501; http://dx.doi.org/10.1016/j.molimm.2010.04.006
32. Scallon BJ, Tam SH, McCarthy SG, Cai AN, Raju TS. Higher levels of sialylated Fc glycans in immunoglobulin G molecules can adversely impact functionality. Mol Immunol 2006; 44:1524-34; PMID:17045339; http://dx.doi.org/10.1016/j.molimm.2006.09.005
33. Kaneko Y, Nimmerjahn F, Ravetch JV. Anti-inflammatory activity of immunoglobulin G resulting from Fc sialylation. Science 2006; 313:670-3; PMID:16888140; http://dx.doi.org/10.1126/science.1129594
34. Liu H, Ponniah G, Zhang HM, Nowak C, Neill A, Gonzalez-Lopez N, Patel R, Cheng G, Kita AZ, Andrien B. In vitro and in vivo modifications of recombinant and human IgG antibodies. mAbs 2014; 6:1145-1154; PMID:29883; http://dx.doi.org/10.4161/mabs
35. Johnson KA, Paisley-Flango K, Tangarone BS, Porter TJ, Rouse JC. Cation exchange-HPLC and mass spectrometry reveal C-terminal amidation of an IgG1 heavy chain. Anal Biochem 2007; 360:75-83; PMID:17113563; http://dx.doi.org/10.1016/j.ab.2006.10.012
36. Bradbury AF, Smyth DG. Peptide amidation. Trends Biochem Sci 1991; 16:112-5; PMID:2057999; http://dx.doi.org/10.1016/0968-0004(91)90044-V
37. Lügering A, Schmidt M, Lügering N, Pauels H-G, Domschke W, Kucharzik T. Infliximab induces apoptosis in monocytes from patients with chronic active Crohn's disease by using a caspase-dependent pathway. Gastroenterology 2001; 121:1145-57; PMID:11677207; http://dx.doi.org/10.1053/gast.2001.28702
38. Horicuchi T, Mitoma H, Harashima S, Tsukamoto H, Shimoda T. Transmembrane TNF-α:structure, function and interaction with anti-TNF agents. Rheumatology 2010; 49:1215-28; PMID:20194223; http://dx.doi.org/10.1093/rheumatology/keq031
39. Peppelenbosch MP, van Deventer SJ. T cell apoptosis and inflammatory bowel disease. Gut 2004; 53(11):1556-58; PMID:15479669; http://dx.doi.org/10.1136/gut.2004.040824
40. Hove T, Van Montfrans CV, Peppelenbosch MP, van Deventer SJH. Infliximab treatment induces apoptosis of lamina propria T lymphocytes in Crohn's disease. Gut 2002; 50:206-11; PMID:11788561; http://dx.doi.org/10.1136/gut.50.2.206
41. Di Sabatino A, Ciccocioppo R, Cinque B, Millimaggi D, Morera R, Ricevuti L, Cifone MG, Corazza GR. Defective mucosal T cell death is sustainably reverted by infliximab in a caspase dependent pathway in Crohn's disease. Gut 2004; 53:70-7; PMID:14684579; http://dx.doi.org/10.1136/gut.53.1.70
42. Suzuki T, Ishii-Watabe A, Tada M, Kobayashi T, Kanayasu-Toyoda T, Kawanishi T, Yamaguchi T. Importance of neonatal FcR in regulating the serum half-life of therapeutic proteins containing the Fc domain of human IgG1:a comparative study of the affinity of monoclonal antibodies and Fc-fusion proteins to human neonatal FcR. J Immunol 2010; 184:1968-76; PMID:20083659; http://dx.doi.org/10.4049/jimmunol.0903296
43. Hermeling S, Crommelin DJ, Schellekens H, Jiskoot W. Structure-immunogenicity relationships of therapeutic proteins. Pharm Res 2004; 21:897-903; PMID:15212151; http://dx.doi.org/10.1023/B:PHAM.0000029275.41323.a6
44. Singh SK. Impact of product-related factors on immunogenicity of biotherapeutics. J Pharm Sci 2011; 100:354-87; PMID:20740683; http://dx.doi.org/10.1002/jps.22276
45. Li CH, Nguyen X, Narhi L, Chemmalil L, Towers E, Muzammil S, Gabrielson J, Jiang Y. Applications of circular dichroism (CD) for structural analysis of proteins:qualification of near- and far-UV CD for protein higher-order structural analysis. J Pharm Sci 2011; 100:4642-54; PMID:21732370; http://dx.doi.org/10.1002/jps.22695
46. Garidel P, Hegyi M, Bassarab S, Weichel M. A rapid, sensitive and economical assessment of monoclonal antibody conformational stability by intrinsic tryptophan fluorescence spectroscopy. Biotechnol J 2008; 3:1201-11; PMID:18702089; http://dx.doi.org/10.1002/biot.200800091